Coherus Oncology, Inc. Common Stock (CHRS) is a publicly traded Healthcare sector company. As of May 21, 2026, CHRS trades at $1.52 with a market cap of $229.83M and a P/E ratio of 0.92. CHRS moved +2.36% today. Year to date, CHRS is +4.86%; over the trailing twelve months it is +85.03%. Its 52-week range spans $0.66 to $2.62. Analyst consensus is strong buy with an average price target of $8.25. Rallies surfaces CHRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
CHRS financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CHRS recently traded at $1.52. Market cap is $229.83M. P/E ratio is 0.92. Revenue is $46.88M.
| Metric | Value |
|---|---|
| Price | $1.52 |
| Market Cap | $229.83M |
| P/E Ratio | 0.92 |
| EPS | $1.64 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.62 |
| 52-Week Low | $0.66 |
| Volume | 5.42K |
| Avg Volume | 0 |
| Revenue (TTM) | $46.88M |
| Net Income | $186.27M |
| Gross Margin | 68.06% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $42.17M | $168.02M | $1.43 |
| 2024 | $266.96M | $28.51M | $0.25 |
| 2023 | $257.24M | $-237.89M | $-2.53 |
| 2022 | $211.04M | $-291.75M | $-3.76 |
5 analysts cover CHRS: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.25.